Vijaya Diagnostic Centre Share News - Latest Updates, Live News & More

Latest news about Vijaya Diagnostic Centre

Vijaya Diagnostic Centre Records ₹16.19 Crore Block Trade on NSE at ₹1257.80 Per Share Jun 12, 2026

Vijaya Diagnostic Centre recorded a block trade on the NSE involving approximately 1,28,705 shares at a price of ₹1257.80 per share. The total transaction value amounted to ₹16.19 crores. Such block trades are significant market events, typically reflecting institutional-level participation and are disclosed to maintain market transparency.

Vijaya Diagnostic Centre CFO resigns effective July 24, 2026 Jun 10, 2026

Vijaya Diagnostic Centre to host investor meet in Singapore Jun 10, 2026

Vijaya Diagnostic Centre CTO Sai Siva Prasad resigns Jun 10, 2026

Vijaya Diagnostic Centre appoints Naga Vasudha Tadepalli as CS Jun 03, 2026

More news about Vijaya Diagnostic Centre

26May 26

Vijaya Diagnostic Centre directors cease tenure on completion

Vijaya Diagnostic Centre Limited disclosed that Non-Executive Independent Directors Mr. Shekhar Prasad Singh and Mr. Satyanaryana Murthy Chavali ceased to hold office effective May 25, 2026, due to the completion of their tenures. The company confirmed there are no other material reasons for the cessation.

26May 26

Vijaya Diagnostic Centre appoints two independent directors

Vijaya Diagnostic Centre has appointed Mr. Satyanaryana Murthy Chavali and Mr. Dipinder Singh Sekhon as Non-Executive Independent Directors for terms of five and two years respectively, effective May 26, 2026, subject to shareholder approval. The appointments were made via a circular resolution by the Board of Directors.

18May 26

Vijaya Diagnostic Centre Sees ₹27.95 Crore Block Trade on NSE at ₹1345.50 Per Share

Vijaya Diagnostic Centre recorded a block trade on the NSE involving approximately 207,713 shares at ₹1345.50 per share. The total value of the transaction stood at ₹27.95 crores. Such block trades are generally associated with institutional participation and are executed to limit price disruption in the open market.

14May 26

Vijaya Diagnostic FY26 Revenue Rises 26.6%

Vijaya Diagnostic Centre Limited reported strong financial results for the year ended March 31, 2026, with consolidated revenue rising 19.5% to INR 814 crores and net profit reaching INR 173 crores. For Q4 FY26, revenue grew 26.6% YoY to INR 219 crores, driven by an 18.5% increase in test volumes, while EBITDA margin expanded to 43.5%. The Board recommended a final dividend of INR 2 per share and approved an ESOP grant. Management announced FY27 expansion plans, including the commissioning of 4 to 5 hubs and 10 to 12 spokes, with a capex outlay of INR 140-150 crores.

12May 26

Vijaya Diagnostic Centre Schedules Analyst and Institutional Investor Meetings on May 20-21, 2026

Vijaya Diagnostic Centre Limited has scheduled analyst and institutional investor meetings on May 20 and May 21, 2026, pursuant to SEBI Regulation 30. The May 20 meeting with Centrum Broking will be held virtually, while the May 21 meeting with Yes Securities will take place in person in Mumbai. The company has confirmed that all discussions will be based on publicly available information, with no unpublished price-sensitive information to be disclosed. The intimation was filed on May 12, 2026, by Chief Financial Officer Ankit Shah.

12May 26

Vijaya Diagnostic Centre Shareholders Approve Two Independent Directors via Postal Ballot

Vijaya Diagnostic Centre Limited concluded its postal ballot process with shareholders approving the appointment of Mr. Ravi Shankararamiah (DIN: 00180746) and Dr. Sasikala Paruchuri Kola (DIN: 00129614) as Independent Directors through Special Resolutions on May 09, 2026. Resolution 1 received 99.9994% votes in favour with 9,62,32,872 valid votes, while Resolution 2 received 99.9995% votes in favour with 9,62,33,049 valid votes, out of 63,545 total shareholders on record as of April 03, 2026.

08May 26

Vijaya Diagnostic Centre Plans ₹140-150 Crore Capital Expenditure for FY27, Eyes Fully Automated Lab in Hyderabad

Vijaya Diagnostic Centre's management has announced a capital expenditure plan of ₹140-150 crore for FY27, as disclosed during a concall update. A major component of this investment is the establishment of a fully automated laboratory in Hyderabad. The initiative reflects the company's strategic focus on advancing its diagnostic infrastructure and operational capabilities.

01May 26

Vijaya Diagnostic Centre announces Q4FY26 earnings conference call for May 8, 2026

Vijaya Diagnostic Centre Limited has announced that it will host an earnings conference call for analysts and investors on Friday, May 8, 2026, at 2:00 PM IST. The call will discuss the financial results for the quarter and financial year ended March 31, 2026. The announcement was made pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Key company executives participating in the call include Ms. Suprita Reddy (Managing Director & Chief Executive Officer), Mr. Siva Rama Raju Vegesna (Chief Operating Officer), Mr. Ankit Shah (Chief Financial Officer), and Mr. Dhiren Gala (Assistant General Manager – Strategy & Investor Relations). The conference call is being organized by JM Financial Institutional Securities Limited. Multiple dial-in options have been provided for participants across different regions, including universal dial-in numbers and toll-free numbers for USA, UK, Singapore, and Hong Kong. Participants are advised to dial in 10 minutes prior to the scheduled time to ensure timely connection.

30Apr 26

Vijaya Diagnostic Centre Records ₹22.47 Crore Block Trade on NSE

Vijaya Diagnostic Centre Ltd. executed a block trade worth ₹22.47 crores on NSE, involving 200,103 shares at ₹1,123.05 per share. The transaction represents significant institutional trading activity in the diagnostic services company.

30Apr 26

Vijaya Diagnostic Centre Limited Board Meeting Intimation for FY26 Scheduled on May 07, 2026

Vijaya Diagnostic Centre Limited's Board meeting scheduled for May 7, 2026, to consider audited financial results for the quarter and year ended March 31, 2026, dividend recommendation, and other corporate matters. Trading window closed from April 1 to May 9, 2026.

09Apr 26

Vijaya Diagnostic Centre Announces Postal Ballot for Independent Director Appointments

Vijaya Diagnostic Centre Limited has issued a postal ballot notice for shareholder approval of two Independent Director appointments. Mr. Ravi Shankararamiah and Dr. Sasikala Paruchuri Kola are proposed for five-year terms from February 13, 2026, to February 12, 2031. Remote e-voting will be conducted from April 10 to May 09, 2026, with results announced by May 12, 2026.

16Mar 26

Vijaya Diagnostic Centre Announces Resignation of Company Secretary Hansraj Singh

Vijaya Diagnostic Centre Limited announced the resignation of Company Secretary & Compliance Officer Hansraj Singh, effective March 16, 2026. Singh cited personal reasons and new career opportunities for his departure, while committing to ensure smooth transition of responsibilities. The company expressed appreciation for his contributions and services during his tenure.

21Feb 26

Wasatch Advisors LP reduces shareholding in Vijaya Diagnostic Centre Ltd to 3.746%

Wasatch Advisors LP has reduced its stake in Vijaya Diagnostic Centre Ltd by selling 23,608 shares through open market transactions on February 19, 2026. The sale decreased the US investment firm's shareholding from 3.769% to 3.746%, leaving it with 3,854,484 shares. The transaction was disclosed under SEBI SAST regulations, with the firm maintaining its position as a non-promoter institutional investor in the diagnostic services company.

14Feb 26

Vijaya Diagnostic Centre Makes Q3FY26 Earnings Call Audio Recording Available

Vijaya Diagnostic Centre Limited has made available the audio recording of its Q3FY26 earnings conference call held on February 13, 2026, following the release of unaudited financial results for the quarter and nine months ended December 31, 2025. The recording is accessible through a direct link and on the company's website under the investors section, with the disclosure made to NSE and BSE on February 14, 2026, in compliance with Regulation 30 requirements.

13Feb 26

Vijaya Diagnostic Centre Announces Key Leadership Appointments and Board Changes

Vijaya Diagnostic Centre has strengthened its leadership team with three key appointments - Ankit Shah as CFO, Sai Prasad as CTO, and Venkata Siva Rama Raju Vegesna as COO. The company also appointed two independent directors and granted 1,15,000 ESOPs under its employee stock option plan.

08Jan 26

Vijaya Diagnostic Centre Allots 1.72 Lakh Shares Following Medinova Merger

Vijaya Diagnostic Centre has successfully completed the final phase of its merger with Medinova Diagnostic Services by allotting 1,71,792 equity shares to eligible shareholders. The Board approved this allotment following the NCLT-approved amalgamation scheme, with special provisions for physical shareholders through a dedicated trust and fractional entitlements handled by an independent trustee.

02Jan 26

Centre Proposes New Rules To Bring Gig Workers Under Social Security Cover

The Centre has released draft rules under the Social Security Code requiring gig workers to work minimum 90-120 days annually with aggregators to qualify for social security benefits. The rules mandate Aadhaar-linked registration for workers above 16 years and establish a National Social Security Board to oversee implementation. Workers will receive health, life and personal accident insurance coverage, with benefits ceasing at age 60 or upon failing to meet minimum workday requirements.

01Jan 26

Centre Considers Relaxing Press Note 3 Rules, May Allow 26% Chinese Investments Without Control Rights

The Centre is reportedly considering relaxing Press Note 3 rules to allow Chinese investments up to 26% in Indian companies without granting control or board rights. This represents a potential shift from current restrictive policies requiring government approval for all Chinese investments. The proposed framework aims to balance economic growth with national security by permitting financial participation while restricting operational control.

17Dec 25

Centre Reviews Coal Sales Limit Policy, Considers Removing 50% Restriction

The Centre has proposed removing the current 50% restriction on coal sales from captive mines. This change could allow captive mine operators more flexibility in managing their coal sales, potentially impacting the coal mining sector's operational framework. The proposal could affect coal availability in domestic markets and influence pricing dynamics.

04Nov 25

Vijaya Diagnostic Centre Reports Q2 Revenue Growth to 2.02B Rupees, Net Profit Up 3.3%

Vijaya Diagnostic Centre announced a 3.3% increase in Q2 consolidated net profit to ₹433 million. Revenue grew by 10.4% to ₹2.02 billion, while EBITDA rose 7.6% to ₹818 million. The company has completed its merger with Medinova Diagnostic Services, effective November 4. Shareholders of Medinova will receive 1 share of Vijaya for every 22 shares held, with November 25 set as the record date. Post-merger, Vijaya's authorized share capital has increased to ₹230.50 million.

18Oct 25

Vijaya Diagnostic Centre Announces CTO Resignation and NCLT Approval for Medinova Merger

Vijaya Diagnostic Centre Limited (VDCL) has announced two significant changes. The company's CTO, Mr. Srinivas Lanka, has resigned effective November 15, 2025, citing personal reasons. Additionally, VDCL has received NCLT approval for its merger with Medinova Diagnostic Services Limited (MDSL). The merger's effective date is pending filing with the Registrar of Companies, Hyderabad. A record date for share allotment to MDSL shareholders will be announced later.

16Oct 25

NCLT Approves Amalgamation of Medinova Diagnostic Services with Vijaya Diagnostic Centre

The NCLT Hyderabad Bench has approved the amalgamation of Medinova Diagnostic Services Limited with Vijaya Diagnostic Centre Limited. The merger, sanctioned on October 13, 2025, with an appointed date of April 1, 2024, involves a share exchange ratio of 1:22. Vijaya Diagnostic Centre's existing 62.14% stake in Medinova will be cancelled. The merger aims to consolidate operations, create synergies, reduce costs, and improve efficiency in the diagnostic services sector. The order ensures regulatory compliance, protects stakeholder interests, and safeguards employee rights. Medinova will be dissolved without winding-up.

01Oct 25

Vijaya Diagnostic Centre's Operations VP to Step Down in November 2025

V. Siva Rama Raju Vegesna, Vice President of Operations at Vijaya Diagnostic Centre, has resigned citing personal reasons. His resignation will be effective from November 8, 2025. Vegesna has been with the company for over six years, contributing to investor relations, strategic initiatives, and market expansion. The company has expressed appreciation for his service and has approximately a year to manage the transition.

29Sept 25

NCLT Hyderabad Reserves Order on Vijaya Diagnostic-Medinova Merger

The National Company Law Tribunal (NCLT) in Hyderabad has reserved its order on the proposed merger between Vijaya Diagnostic Centre Limited and Medinova Diagnostic Services Limited. The merger, with an appointed date of April 1, 2024, is based on a going concern basis under Sections 230 to 232 of the Companies Act, 2013. Vijaya Diagnostic Centre has reported that the attendance-cum-order sheet recording the 'Orders Reserved' status is available on the NCLT website. The company awaits the certified true copy of the order to submit to stock exchanges.

02Aug 25

Vijaya Diagnostic Centre Reports 20.4% Revenue Growth in Q1

Vijaya Diagnostic Centre reported consolidated revenue of Rs. 188.00 crores for Q1, a 20.4% year-on-year growth. The company saw a 17% increase in test volume and 14% rise in patient footfall. EBITDA margin was 39.1% and PAT margin 20.4%. The core Hyderabad market returned to double-digit growth. Five new hubs and one spoke were commissioned across Pune, Bangalore, and West Bengal. The company maintains a strong financial position with a cash balance of Rs. 270.00 crores. Future plans include opening 10 hubs in the current financial year with a CAPEX of Rs. 150.00-155.00 crores for new centers.

28Jul 25

Vijaya Diagnostic Centre Announces Robust Q1 Results and Ambitious Expansion Plans

Vijaya Diagnostic Centre reported impressive Q1 results with 20.4% revenue growth to Rs 1,880.50 crore, 20.1% EBITDA growth to Rs 735.30 crore, and 22.3% PAT growth to Rs 383.40 crore. The company performed 3.94 million tests, a 16.7% increase, with 1.10 million footfalls. Expansion plans include launching 3 new hubs in Q2 and 2 more in West Bengal later this fiscal year. The company aims to achieve break-even across all centers within 12 months, with one Bengaluru hub progressing faster than expected.

28Jul 25

Vijaya Diagnostic Centre Reports Robust Q1 FY26 Performance with 20.5% Revenue Growth

Vijaya Diagnostic Centre announced strong Q1 FY26 results with revenue increasing 20.5% to ₹188.05 crore. Net profit rose 23.1% to ₹38.59 crore, while EBITDA grew to ₹73.50 crore with a margin of 39.10%. The company granted 2,500 ESOPs, appointed a new Secretarial Auditor, and is progressing with a proposed merger with its subsidiary, Medinova Diagnostic Services Limited.

08Jul 25

Vijaya Diagnostic Centre Ltd. Sees Rs. 23.13 Crore Block Trade on NSE

A significant block trade of 230,405 shares of Vijaya Diagnostic Centre Ltd. was executed on the National Stock Exchange (NSE). The transaction was valued at Rs. 23.13 crore, with each share priced at Rs. 1,004.00. This large trade indicates potential shifts in ownership or strategic moves by major shareholders, although the identities of the buyer and seller remain undisclosed. Such transactions can influence market sentiment and the stock's trading pattern in the short term.

12May 25

Vijaya Diagnostic Centre Reports Q4 Growth in EBITDA and Net Profit, Declares Dividend

Vijaya Diagnostic Centre's Q4 results show significant growth across key financial metrics. Revenue increased by 26.05% to ₹173.70 crore, EBITDA rose by 29.60% to ₹71.80 crore, and net profit grew by 35.77% to ₹35.30 crore year-over-year. The company's EBITDA margin improved to 41.34%, and it declared a dividend of ₹2.00 per share. Operating profit reached ₹67.10 crore with a margin of 39.73%, indicating strong core operational performance.

Vijaya Diagnostic Centre

1,367.80

+55.20

(+4.21%)

1 Year Returns:+45.50%

Industry Peers

Dr. Lal Path Labs

1,689.20

(+2.00%)

Vijaya Diagnostic Centre

1,367.80

(+4.21%)

Metropolis Healthcare

543.35

(-1.78%)

Thyrocare Technologies

517.20

(-6.94%)

Nephrocare Health Services

657.95

(-3.21%)

Krsnaa Diagnostics

538.25

(+0.13%)

One Global Service Provider

743.15

(-1.07%)

Suraksha Diagnostic

271.65

(-0.09%)

Health X Platform

328.25

(+1.61%)

3B BlackBio DX

1,159.70

(-0.92%)

Get More Market Insights with

Stock Rental via SLBM

About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.
We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.
This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.
The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.
We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.
This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.
By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.
We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.

Part of Raise Financial Services

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016 | SEBI Research Analyst Registration No: INH000023357 Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104